{
  "docId": "019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "docSlug": "213575480fcc7466657230c6a0d87626",
  "documentTitle": "23andMe | Investor Day Presentation Deck | 78 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 78,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f0b8-737f-9ff6-e8b6f7a1e960/5",
  "deckHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "deckJsonHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960.json",
  "deckAnchorHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.93,
        "x": 0.046,
        "y": 0.598
      },
      "kind": "list",
      "text": "23andMe elects for royalty option on collaboration program targeting CD96. 23andMe will be eligible to earn tiered worldwide royalties up to the low double digits. The worldwide royalty option curtails 23andMe’s future investment in this program and provides 23andMe with a potentially high value revenue stream if the program is successful.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3569ae51-4019-48fe-9cb2-840eaadb794d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.908,
        "x": 0.046,
        "y": 0.185
      },
      "kind": "list",
      "text": "GSK has elected to extend the exclusive target discovery period of the collaboration for a fifth year. We will continue to discover and validate novel drug targets using 23andMe’s proprietary genetic and health survey database. 23andMe will receive a one-time payment of $50 million.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b18cea53-8bb4-4fc8-bf86-39123a50585d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.102,
        "w": 0.722,
        "x": 0.046,
        "y": 0.046
      },
      "kind": "title",
      "text": "Today's News on 23andMe and GSK Collaboration",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54efd8f3-213a-41a7-979a-8ce71879772e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "de8ae9bb-4ff0-4053-b7a4-68889e6e024c",
      "evidence": "list/bullet: 23andMe elects for royalty option on collaboration program targeting CD96. 23andMe will be eligible to earn tiered worldwide royalties up to the low double digits. The worldwide royalty option curtails 23and list/bullet: GSK has elected to extend the exclusive target discovery period of the collaboration for a fifth year. We will continue to discover and validate novel drug targets us",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}